ClinicalTrials.gg
CompletedNCT04763421Updated Sep 24, 2024Results posted

A Prospective, Single-Arm Multi-Center Study of the ENSEAL X1 Curved Jaw Tissue Sealer in Select Procedures

An interventional study of ENSEAL X1 Curved Jaw in Upper GI; Lower GI; Gynecological, sponsored by Ethicon Endo-Surgery. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Ethicon Endo-Surgery (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This prospective, single-arm, multi-center study will collect clinical data in a post-market setting by procedure group (upper gastrointestinal [GI], lower GI, and gynecological). Investigators will perform each procedure using the device in compliance with their standard surgical approach and the ENSEAL X1 Curved Jaw and Generator G11 instructions for use.

Read the detailed description

The primary objective of this study is to demonstrate the acceptable performance and safety of the ENSEAL X1 Curved Jaw and Generator G11 devices when used per the instructions for use.

02

Conditions studied

  • Upper GI; Lower GI; Gynecological
03

In context

Lead sponsor

Ethicon Endo-Surgery is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primary laparoscopic or open procedure (upper gastrointestinal, lower gastrointestinal, or gynecological) where at least one vessel is planned to be transected by the ENSEAL X1 Curved Jaw device per the instructions for use;
  2. Willingness to give consent and comply with all study-related evaluations and visit schedule; and
  3. At least 18 years of age.

Exclusion criteria

Exclusion Criteria:

  1. Physical or psychological condition which would impair study participation; or
  2. Enrollment in a concurrent interventional clinical study that could impact the study endpoints.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Upper Gastrointestinal/Lower Gastrointestinal/Gynecological

    Any upper gastrointestinal/lower gastrointestinal/gynecological procedure where the ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.

    Device: ENSEAL X1 Curved Jaw

Interventions

  • DeviceENSEAL X1 Curved Jaw

    ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.

06

What researchers measure

Primary outcomes

  1. Number of Vessels With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale

    Number of vessels with \<= Grade 3 hemostasis based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with ENSEAL X1; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

    Time frame: On the day of transection (Day 0)

  2. Number of Participants With Device-related Adverse Events (AEs)

    Number of participants with device-related AEs were reported. Device-related AEs were those AEs identified as having a relationship of possibly, probably, or causally with the study devices.

    Time frame: From Day 0 up to post-procedure follow up visit (up to 28 days)

Secondary outcomes

  1. Number of Participants With Adhesion Removal or Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

    Number of participants with adhesion removal or division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for adhesion removal or division by ENSEAL X1.

    Time frame: On the day of transection (Day 0)

  2. Number of Participants With Lymphatics Bundles Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

    Number of participants with lymphatics bundles division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for lymphatic bundles by ENSEAL X1.

    Time frame: On the day of transection (Day 0)

  3. Number of Participants With Tissues Bundles Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

    Number of participants with tissues bundles division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues bundles by ENSEAL X1.

    Time frame: On the day of transection (Day 0)

  4. Number of Participants With Tissues Grasping Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

    Number of participants with tissues grasping using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues grasping by ENSEAL X1.

    Time frame: On the day of transection (Day 0)

  5. Number of Participants With Tissues Cutting Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

    Number of participants with tissues cutting using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues cutting by ENSEAL X1.

    Time frame: On the day of transection (Day 0)

  6. Number of Participants With Tissues Dissection Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

    Number of participants with tissues dissection using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues dissection by ENSEAL X1.

    Time frame: On the day of transection (Day 0)

  7. Number of Vessels With Hemostasis (Grade 1 to 4) Based on Hemostasis Grading Scale

    Number of vessels with hemostasis (Grade 1 to 4) based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with ENSEAL X1; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

    Time frame: On the day of transection (Day 0)

  8. Percentage of Grade 4 Vessel Transections Requiring Hemostasis Measures

    Percentage of Grade 4 vessel transections requiring hemostasis measures were planned to be reported. Data was not collected and analyzed for this outcome measure because there were no hemostatic grade 4 vessel transections.

    Time frame: On the day of transection (Day 0)

07

Results

Posted Sep 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneENSEAL X1 Curved Jaw
Started145
Completed145
Not completed0

Outcome measures

PrimaryNumber of Vessels With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale

Number of vessels with \<= Grade 3 hemostasis based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with ENSEAL X1; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

Time frame:
On the day of transection (Day 0)
Reported as:
Count of units · Vessels transected
Number of Vessels With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale
Vessels transectedENSEAL X1 Curved Jaw
Number of Vessels With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale279
PrimaryNumber of Participants With Device-related Adverse Events (AEs)

Number of participants with device-related AEs were reported. Device-related AEs were those AEs identified as having a relationship of possibly, probably, or causally with the study devices.

Time frame:
From Day 0 up to post-procedure follow up visit (up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Device-related Adverse Events (AEs)
ParticipantsENSEAL X1 Curved Jaw
Number of Participants With Device-related Adverse Events (AEs)2
SecondaryNumber of Participants With Adhesion Removal or Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

Number of participants with adhesion removal or division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for adhesion removal or division by ENSEAL X1.

Time frame:
On the day of transection (Day 0)
Reported as:
Count of participants · Participants
Number of Participants With Adhesion Removal or Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
ParticipantsENSEAL X1 Curved Jaw
Very Dissatisfied0
Dissatisfied0
Neither Satisfied or Dissatisfied1
Satisfied27
Very Satisfied21
SecondaryNumber of Participants With Lymphatics Bundles Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

Number of participants with lymphatics bundles division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for lymphatic bundles by ENSEAL X1.

Time frame:
On the day of transection (Day 0)
Reported as:
Count of participants · Participants
Number of Participants With Lymphatics Bundles Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
ParticipantsENSEAL X1 Curved Jaw
Very Dissatisfied0
Dissatisfied0
Neither Satisfied or Dissatisfied1
Satisfied18
Very Satisfied8
SecondaryNumber of Participants With Tissues Bundles Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

Number of participants with tissues bundles division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues bundles by ENSEAL X1.

Time frame:
On the day of transection (Day 0)
Reported as:
Count of participants · Participants
Number of Participants With Tissues Bundles Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
ParticipantsENSEAL X1 Curved Jaw
Very Dissatisfied0
Dissatisfied0
Neither Satisfied or Dissatisfied1
Satisfied26
Very Satisfied28
SecondaryNumber of Participants With Tissues Grasping Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

Number of participants with tissues grasping using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues grasping by ENSEAL X1.

Time frame:
On the day of transection (Day 0)
Reported as:
Count of participants · Participants
Number of Participants With Tissues Grasping Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
ParticipantsENSEAL X1 Curved Jaw
Very Dissatisfied0
Dissatisfied4
Neither Satisfied or Dissatisfied9
Satisfied31
Very Satisfied23
SecondaryNumber of Participants With Tissues Cutting Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

Number of participants with tissues cutting using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues cutting by ENSEAL X1.

Time frame:
On the day of transection (Day 0)
Reported as:
Count of participants · Participants
Number of Participants With Tissues Cutting Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
ParticipantsENSEAL X1 Curved Jaw
Very Dissatisfied1
Dissatisfied1
Neither Satisfied or Dissatisfied3
Satisfied38
Very Satisfied44
SecondaryNumber of Participants With Tissues Dissection Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score

Number of participants with tissues dissection using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues dissection by ENSEAL X1.

Time frame:
On the day of transection (Day 0)
Reported as:
Count of participants · Participants
Number of Participants With Tissues Dissection Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
ParticipantsENSEAL X1 Curved Jaw
Very Dissatisfied0
Dissatisfied0
Neither Satisfied or Dissatisfied3
Satisfied59
Very Satisfied45
SecondaryNumber of Vessels With Hemostasis (Grade 1 to 4) Based on Hemostasis Grading Scale

Number of vessels with hemostasis (Grade 1 to 4) based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with ENSEAL X1; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

Time frame:
On the day of transection (Day 0)
Reported as:
Count of units · vessels transected
Number of Vessels With Hemostasis (Grade 1 to 4) Based on Hemostasis Grading Scale
vessels transectedENSEAL X1 Curved Jaw
Grade 1258
Grade 212
Grade 39
Grade 40
SecondaryPercentage of Grade 4 Vessel Transections Requiring Hemostasis Measures

Percentage of Grade 4 vessel transections requiring hemostasis measures were planned to be reported. Data was not collected and analyzed for this outcome measure because there were no hemostatic grade 4 vessel transections.

Time frame:
On the day of transection (Day 0)

No measurements were reported for this outcome.

Adverse events

Collected over From Day 0 up to post-procedure follow up visit (Up to 28 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ENSEAL X1 Curved Jaw0/145 (0%)10/145 (6.9%)58/145 (40%)
Most frequent serious events
Most frequent serious events
EventENSEAL X1 Curved Jaw
Abdominal painGastrointestinal disorders1/145
IleusGastrointestinal disorders1/145
Intra-abdominal haematomaGastrointestinal disorders1/145
CellulitisInfections and infestations1/145
Septic shockInfections and infestations1/145
Procedural painInjury, poisoning and procedural complications1/145
Vaginal haemorrhageReproductive system and breast disorders1/145
PneumothoraxRespiratory, thoracic and mediastinal disorders1/145
Lymphatic fistulaVascular disorders1/145
Pelvic venous thrombosisVascular disorders1/145
Most frequent other events
Showing 10 of 48
Most frequent other events
EventENSEAL X1 Curved Jaw
NauseaGastrointestinal disorders21/145
PainGeneral disorders14/145
VomitingGastrointestinal disorders10/145
Procedural painInjury, poisoning and procedural complications10/145
Abdominal painGastrointestinal disorders8/145
ConstipationGastrointestinal disorders7/145
IleusGastrointestinal disorders4/145
PyrexiaGeneral disorders4/145
Abdominal pain upperGastrointestinal disorders3/145
Incision site painInjury, poisoning and procedural complications3/145

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ENSEAL X1 Curved Jaw
Mean55.28 ± 15.904
Sex: Female, Male
Sex: Female, Male(Participants)ENSEAL X1 Curved Jaw
Female101
Male44
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ENSEAL X1 Curved Jaw
Hispanic or Latino5
Not Hispanic or Latino135
Unknown or Not Reported5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ENSEAL X1 Curved Jaw
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American6
White133
More than one race0
Unknown or Not Reported5
08

Study locations

6 sites
  • Atrium Health
    Charlotte, North Carolina 28204, United States
  • Gemelli Hospital
    Rome, Italy
  • Southmead Hospital
    Bristol, United Kingdom
  • Royal Infirmary of Edinburgh
    Edinburgh, United Kingdom
  • Western General Hospital
    Edinburgh, United Kingdom
  • Yeovil District Hospital
    Yeovil, BA21 4AT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Aug 2023, 28 months.

Results were first posted in Sep 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2021
First posted
Feb 21, 2021
StartActual
Apr 22, 2021
Primary completionActual
Aug 30, 2023
CompletionActual
Sep 29, 2023
Results first posted
Sep 24, 2024
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04763421
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Apr 22, 2021
Primary completion
Aug 30, 2023
Completion
Sep 29, 2023
Results posted
Sep 24, 2024
Last update
Sep 24, 2024

Study contacts

Ahmar Shah, MD
principal investigator · Yeovil District Hospital
Anna Fagotti, MD
principal investigator · Gemelli Hospital
Sergio Alfieri, MD
principal investigator · Gemelli Hospital
Richard Skipworth, MD
principal investigator · Royal Infirmary of Edinburgh
Hugh Paterson, MD
principal investigator · Western General Hospital
Keith Gersin, MD
principal investigator · Wake Forest University Health Sciences
James Hopkins, MD
principal investigator · Southmead Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion